ABBV vs LEN · P/E 81, rev $61.16B vs rev $34.19B
AbbVie Inc (ABBV) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
LEN (LEN) common stock.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. LEN currently screens at market cap $0.
Not investment advice. Open the ABBV and LEN stock pages for the full models.
Not investment advice.